{"gene":"NRG1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1993,"finding":"NDF (NRG1) binds with high affinity (Kd ~10^-9 M) to mammary cells via Neu/HER-2 and an additional cellular co-component; direct radiolabeled cross-linking showed covalent association with Neu in breast but not ovarian cells, and NDF-induced Neu activation was coupled to PI3-kinase association in a cell-type-specific manner.","method":"Radiolabeled NDF cross-linking, monoclonal antibody blocking, direct binding analysis, PI3K co-immunoprecipitation","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct binding assay with Kd measurement, covalent crosslinking, and PI3K co-IP; multiple orthogonal methods in one study","pmids":["8096177"],"is_preprint":false},{"year":1994,"finding":"NDF (NRG1) stimulates tyrosine phosphorylation of Her3/ErbB3, and chemical crosslinking of radiolabeled NDF to cells immunoprecipitated with anti-Her3 reveals a high-molecular-weight complex (>400 kDa), indicating NDF is a ligand for ErbB3 that induces receptor hetero-oligomerization.","method":"Tyrosine phosphorylation assay, 125I-NDF crosslinking, immunoprecipitation","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — radiolabeled ligand crosslinking plus immunoprecipitation and phosphorylation assay; two orthogonal methods establishing ErbB3 as NDF receptor","pmids":["8045292"],"is_preprint":false},{"year":1995,"finding":"NDF (NRG1) activates MAP kinase (p44ERK1/p42ERK2) and p70/p85 S6 kinase, and stimulates tyrosine phosphorylation and in vitro kinase activity of ErbB-2 in mammary epithelial cells; PKC activation by TPA blocks NDF-induced ErbB-2 activation and cell proliferation.","method":"In vitro kinase assay, MAP kinase activation assay, TPA-mediated PKC activation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay plus pathway activation assays with pharmacologic perturbation across multiple cell lines","pmids":["7824269"],"is_preprint":false},{"year":1996,"finding":"ErbB-2 forms heterodimers with EGF receptor (ErbB-1) and NDF receptors (ErbB-3 and ErbB-4); ErbB-2 overexpression enhances binding affinity to NDF by decelerating ligand dissociation, while ER-trapped anti-ErbB-2 antibody removes ErbB-2 from cell surface and almost completely abolishes NDF binding by accelerating dissociation. These kinetic effects prolong MAP kinase (ERK) and c-Jun kinase (SAPK) activation.","method":"Co-immunoprecipitation of heterodimers, intracellular antibody (ER-trap) blocking, ligand dissociation kinetics, ERK/SAPK activation assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reciprocal co-IP, gain- and loss-of-function (overexpression + ER-trap antibody), ligand kinetics, and downstream signaling; multiple orthogonal methods replicated across cell types","pmids":["8617201"],"is_preprint":false},{"year":1996,"finding":"GGF/neuregulin (NRG1) acts as a mitogen and survival factor for oligodendrocyte progenitors (O4+/O1- cells) and oligodendrocytes; high GGF levels reversibly inhibit differentiation and lineage commitment. GGF activates all three ErbB receptors expressed by progenitors (ErbB2, ErbB3, ErbB4). Cortical neurons release a soluble GGF-like mitogen for pro-oligodendrocytes that is blocked by anti-GGF antibodies.","method":"Cell proliferation/survival assays, ErbB receptor activation assays, antibody blocking of conditioned medium","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional cell assays with receptor activation measurement and antibody blocking; multiple orthogonal experiments in a single study","pmids":["8780647"],"is_preprint":false},{"year":1996,"finding":"GGF/neuregulin (NRG1) promotes survival and neurite extension from embryonic and neonatal rat retinal neurons in a dose-dependent manner, with effects correlating with erbB2/neu expression levels during retinal development.","method":"Dissociated retinal cell cultures, neuronal survival and neurite outgrowth assays, receptor expression analysis","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional assays with dose-response and receptor correlation; single lab, single cell-type system","pmids":["8625831"],"is_preprint":false},{"year":1997,"finding":"GGF (NRG1) promotes neuronal migration along radial glial fibers and maintenance/elongation of radial glial cells during cortical development; loss of GGF signaling via ErbB2 receptors causes abnormal radial glial development. GGF's regulation of radial glia is mediated in part through brain lipid-binding protein (BLBP).","method":"In vitro neuronal migration assays, ErbB2-deficient mouse models, BLBP expression analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function genetic model plus in vitro functional assays identifying BLBP as downstream mediator; two orthogonal approaches","pmids":["9342043"],"is_preprint":false},{"year":1997,"finding":"ErbB-3 (NDF/NRG1 receptor) is expressed primarily in epithelial layers, peripheral nervous system, and adult brain; ErbB-4 is restricted to developing CNS and embryonic heart. Blocking endogenous NDF with soluble ErbB-4 accelerated neurite outgrowth in primary brain cultures and P19 teratocarcinoma, demonstrating an inhibitory role of NDF on neural differentiation. ErbB-3 is associated with proliferation while ErbB-4 correlates with differentiated phenotype in P19 cells.","method":"Soluble receptor blocking, primary brain culture neurite outgrowth assay, P19 differentiation assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — soluble receptor blocking with functional readout (neurite outgrowth) plus receptor-phenotype correlation; two orthogonal approaches","pmids":["9419971"],"is_preprint":false},{"year":1997,"finding":"NDF/NRG1 activates ErbB3-ErbB2 crosstalk in LNCaP prostate cells without involving ErbB1; NDF activates PI3K (forming an 'activation complex' with ErbB3), ERK/MAPK, mHOG/p38, and JNK/SAPK pathways, but not PLCγ or STAT family signaling, demonstrating a distinct signaling pattern from TGF-α.","method":"Tyrosine phosphorylation assays, PI3K co-immunoprecipitation, pathway activation assays in prostate cell lines","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple pathway assays in a single cell line model; comprehensive but single lab","pmids":["9400997"],"is_preprint":false},{"year":1997,"finding":"Schwann cells secrete a ~45 kDa neuregulin protein (NRG1) and show constitutive activation of ErbB3, indicating an autocrine loop. Anti-neuregulin antibody inhibited Schwann cell proliferation stimulated by neurons and by multiple unrelated mitogens (bFGF, HGF, TGF-β1), implicating NRG1 autocrine signaling in Schwann cell mitogenic responses.","method":"ELISA detection of secreted neuregulin, ErbB3 phosphorylation assays, antibody neutralization of proliferation assays","journal":"Experimental neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — secretion detection plus constitutive receptor activation plus antibody neutralization functional assay; multiple orthogonal methods","pmids":["9417836"],"is_preprint":false},{"year":1999,"finding":"GGF/NRG1 induces phenotypic reversion of differentiated oligodendrocytes: loss of MBP expression, re-expression of nestin, reorganization of actin cytoskeleton, and reduction in process number. GGF is not cytotoxic but enhances survival. GGF rapidly activates PI3-kinase and MAP kinase signaling pathways in oligodendrocytes.","method":"TUNEL assay, immunostaining for MBP/nestin, PI3K and MAPK activation assays","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple phenotypic readouts with parallel pathway activation assays; functional consequence clearly tied to signaling","pmids":["10192767"],"is_preprint":false},{"year":2009,"finding":"Erbin, a PDZ domain protein that interacts specifically with ErbB2, is required for NRG1 signaling and myelination of the peripheral nervous system. Erbin stabilizes ErbB2 protein; loss of the Erbin PDZ domain causes ErbB2 instability and compromised NRG1 signaling. Erbin null mice and erbin(DeltaC/DeltaC) mice show hypomyelination, aberrant Remak bundle formation, reduced nerve conduction velocity, and sensory threshold changes.","method":"Genetic knockout/knock-in mouse models, ErbB2 protein stability assays, nerve conduction velocity measurement, co-immunoprecipitation of Erbin-ErbB2","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (null + PDZ-deletion knockin) with mechanistic follow-up (ErbB2 stabilization by Erbin-ErbB2 interaction) and functional phenotypic readouts","pmids":["19458253"],"is_preprint":false},{"year":2009,"finding":"NRG1/ERBB3 signaling inhibits melanocyte maturation and promotes undifferentiated, migratory, and proliferative characteristics; NRG1/ERBB3 signaling is necessary and sufficient to inhibit differentiation of late-stage melanocyte progenitors in culture. NRG1 treatment increases proliferation and invasion of melanocytes with decreased differentiation gene expression.","method":"ERBB3-deficient embryonic analysis, NRG1 treatment of melanocyte cultures, proliferation/invasion assays, gene expression analysis","journal":"Pigment cell & melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (ERBB3-deficient) plus gain-of-function (NRG1 treatment) with multiple functional and molecular readouts","pmids":["19659570"],"is_preprint":false},{"year":2010,"finding":"LH induces NRG1 type III transcripts in granulosa cells via ERK1/2 and C/EBPβ-dependent mechanisms. NRG1 (intact 75 kDa and secreted 45 kDa forms) binds to ERBB3/ERBB2 complexes in granulosa cells and selectively stimulates AKT phosphorylation over ERK1/2. NRG1 potentiates AREG-induced ERK1/2 phosphorylation and progesterone production, and enhances oocyte developmental competence in cumulus-oocyte complexes.","method":"Western blotting, receptor phosphorylation assays, progesterone measurement, oocyte developmental competence assay","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional and biochemical readouts in granulosa cell and COC systems; single lab","pmids":["21047912"],"is_preprint":false},{"year":2011,"finding":"Each of the six NRG1 isoform types has a distinct expression pattern in the brain at different developmental ages. Types I, II, and III are predominantly expressed in excitatory neurons. Neuronal activity specifically regulates NRG1 isoform expression: type I and IV NRG1 levels increase with neuronal activity. Type IV regulation requires a CRE cis-element in the 5' UTR that binds to CREB.","method":"Isoform-specific qPCR, in situ hybridization, CRE mutant reporter assay, ChIP-like analysis","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — activity-dependent regulation with CRE reporter assay identifying CREB binding; two orthogonal methods","pmids":["21653853"],"is_preprint":false},{"year":2013,"finding":"NRG1 (ErbB2 ligand) inhibits GDNF-induced neuronal differentiation of mouse neural crest cells (enteric neuron precursors), while GDNF negatively regulates NRG1 signaling by down-regulating ErbB2 expression, establishing a functional interaction between RET/GDNF and NRG1/ERBB2 pathways in enteric nervous system development.","method":"Primary neural crest cell culture, neuronal differentiation assay, ErbB2 expression analysis after GDNF treatment","journal":"Human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional cell culture assay with receptor expression measurement; single lab with limited mechanistic depth","pmids":["23400839"],"is_preprint":false},{"year":2014,"finding":"CD74-NRG1 gene fusion leads to extracellular expression of the EGF-like domain of NRG1 III-β3, providing the ligand for ERBB2-ERBB3 receptor complexes. Ectopic expression of CD74-NRG1 in lung cancer cell lines expressing ERBB2 and ERBB3 activated ERBB3 and the PI3K-AKT pathway, and promoted anchorage-independent colony formation.","method":"Transcriptome sequencing, ectopic expression in cell lines, receptor phosphorylation assays, soft agar colony formation assay","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ectopic expression with phospho-receptor readout and functional colony assay; replicated across multiple tumor specimens and cell lines","pmids":["24469108"],"is_preprint":false},{"year":2014,"finding":"NRG1 activates NR2B (GluN2B) phosphorylation through ErbB4, and TrkB interacts with ErbB4 (shown by co-immunoprecipitation and proximity ligation assay); this TrkB-ErbB4 interaction increases upon NRG1 treatment. TrkB inhibition (K252a, siRNA, TrkB-/- neurons) suppresses NRG1-induced NR2B activation. NRG1-induced BDNF release (via GABAAR-TrkB) mediates phospho-TrkB and phospho-NR2B increases; BDNF neutralization abolishes these effects.","method":"Co-immunoprecipitation, proximity ligation assay, TrkB siRNA/knockout neurons, pharmacologic inhibition (K252a, AG1478), BDNF neutralization","journal":"Cell communication and signaling : CCS","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct protein interaction assays (co-IP + PLA) combined with multiple genetic and pharmacologic loss-of-function experiments, convergent mechanistic pathway","pmids":["25052836"],"is_preprint":false},{"year":2014,"finding":"NRG1-ErbB4 signaling in the basolateral amygdala (BLA) modulates anxiety-like behaviors and GABA release but has no effect on glutamatergic transmission. ErbB4 is expressed almost exclusively in GABAergic neurons in the BLA; NRG1 administration into BLA alleviates anxiety and enhances GABAergic neurotransmission.","method":"Stereotactic NRG1 injection into BLA, electrophysiology (GABA release measurement), behavioral anxiety tests","journal":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacologic activation with electrophysiology and behavioral readouts; mechanistic pathway placement in GABAergic interneurons","pmids":["25308353"],"is_preprint":false},{"year":2015,"finding":"CD74-NRG1 expression activates ErbB2/3 phosphorylation, PI3K/Akt/NF-κB signaling, and promotes cancer stem cell-like properties. NF-κB-dependent IGF2 expression and IGF1R phosphorylation are enhanced in CD74-NRG1-expressing cells, creating an IGF2 autocrine/paracrine circuit. Inhibition of ErbB2, PI3K, NF-κB, or IGF2 suppresses CD74-NRG1-induced tumor sphere formation.","method":"Ectopic expression, phospho-receptor/pathway assays, sphere formation assay, limiting dilution xenograft, pharmacologic inhibition","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including in vitro signaling assays, in vivo xenograft, and pharmacologic dissection of pathway components","pmids":["26837769"],"is_preprint":false},{"year":2015,"finding":"DISC1 inhibits NRG1-induced ErbB4 activation and signaling in cortical interneurons; this inhibition is likely mediated by competitive inhibition of ErbB4 binding to PSD95. Cell-type-specific modulation of DISC1 in vitro and in vivo (including mutant DISC1 mouse model) demonstrated that DISC1 affects NRG1-ErbB4-mediated phenotypes in fast-spiking interneuron-pyramidal neuron circuits.","method":"Cell-type-specific gene modulation in vitro/in vivo, mutant DISC1 knock-in mouse, ErbB4/PSD95 binding competition assay, electrophysiology","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic in vivo model plus mechanistic binding competition assay plus electrophysiology; multiple orthogonal methods","pmids":["26656849"],"is_preprint":false},{"year":2015,"finding":"Paracrine NRG1 from fibroblasts activates ERBB3 on uveal melanoma cells and provides resistance to MEK inhibitor trametinib; ERBB3 inhibition combined with MEK inhibition overcomes this resistance. Trametinib treatment enhances responsiveness to NRG1. AKT inhibition reverses the NRG1-mediated protective effect.","method":"Conditioned medium experiments, ERBB3/cMET inhibitor experiments, xenograft models, AKT inhibition rescue","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — paracrine mechanism established by conditioned medium + target inhibition experiments in vitro and in vivo; two orthogonal approaches","pmids":["25952648"],"is_preprint":false},{"year":2016,"finding":"A RET-ER81-NRG1 signaling pathway in mechanosensory neurons is required for Pacinian corpuscle formation. ER81 is required downstream of RET for maintaining interaction with nonmyelinating Schwann cells; ER81 loss reduces NRG1 isoform expression (specifically the isoform not involved in myelination). Ablating Nrg1 in mechanosensory neurons eliminates Pacinian corpuscles, establishing a distinct NRG1 isoform-dependent pathway for axon-nonmyelinating Schwann cell communication.","method":"Genetic ablation (Er81 mutant, Nrg1 conditional knockout in neurons), Pacinian corpuscle histology, isoform-specific expression analysis","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple conditional genetic models with clear anatomical phenotype; epistasis established between RET, ER81, and NRG1 isoforms","pmids":["27707970"],"is_preprint":false},{"year":2015,"finding":"VAMP2-NRG1 fusion gene is membrane-bound, displays the NRG1 EGF-like domain extracellularly, and promotes anchorage-independent colony formation in lung adenocarcinoma cells. Ectopic VAMP2-NRG1 expression stimulates phosphorylation of ERBB2, ERBB3, AKT, and ERK, confirming ERBB2/ERBB3 pathway activation as oncogenic mechanism.","method":"Whole-transcriptome sequencing, RT-PCR, immunoblotting, soft agar colony formation assay","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay (soft agar) plus phospho-signaling readout from ectopic expression; two orthogonal methods","pmids":["26134228"],"is_preprint":false},{"year":2017,"finding":"Spironolactone acts as an antagonist of NRG1-ERBB4 signaling; it inhibits ERBB4 receptor phosphorylation and reverts cortical ERBB4 hyperphosphorylation in Nrg1 type III transgenic mice. Spironolactone increases spontaneous inhibitory postsynaptic currents in cortical slices, supporting ERBB4-mediated mode of action.","method":"Cell-based split TEV assay (compound screen), ERBB4 phosphorylation assay in transgenic mice, electrophysiology (cortical slice sIPSCs), behavioral tests","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstituted cell-based assay for drug screening plus in vivo transgenic validation plus electrophysiology; multiple orthogonal methods","pmids":["28743784"],"is_preprint":false},{"year":2017,"finding":"NRG1 regulates Fra-1 expression and TNBC metastasis via the ERK1/2-Fbxw7-c-Myc pathway: NRG1 activates ERK1/2, which phosphorylates Fbxw7 and promotes its dissociation and nuclear import of c-Myc; c-Myc then drives Fra-1 transcription. NRG1 knockdown suppresses TNBC cell metastasis and Fra-1 downregulation.","method":"NRG1 knockdown, ERK1/2 activation assays, ubiquitination assays (Fbxw7-c-Myc), ChIP (c-Myc on Fra-1 promoter), metastasis assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissection via multiple molecular assays (ubiquitination, ChIP, kinase) in a single lab; mechanistic chain established","pmids":["34992218"],"is_preprint":false},{"year":2018,"finding":"NRG1 fusions in pancreatic ductal adenocarcinoma (e.g., ATP1B1-NRG1, RBPMS-NRG1) drive ERBB receptor-mediated signaling. Pharmacologic ERBB inhibition (afatinib) resulted in clinical remission, functionally validating NRG1 fusions as ERBB pathway-activating oncogenic drivers in KRAS wild-type PDAC.","method":"Whole-genome and transcriptome sequencing, clinical ERBB inhibitor treatment with imaging response","journal":"Cancer discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genomic identification plus clinical pharmacologic validation; functional mechanism inferred from therapeutic response","pmids":["29802158"],"is_preprint":false},{"year":2018,"finding":"NRG1-Fc (NRG1 fused to IgG1 Fc) triggers potent AKT activation in the liver, lowers blood glucose, improves insulin sensitivity, and suppresses food intake in obese mice. NRG1-Fc acts as a FGF21 secretagogue; however, FGF21 is largely dispensable for its metabolic effects. NRG1-Fc directly targets hypothalamic POMC neurons to promote membrane depolarization and increase firing rate.","method":"NRG1-Fc fusion protein engineering, AKT phosphorylation assays, FGF21 neutralization, electrophysiology of POMC neurons, metabolic measurements in obese mice","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — engineered fusion protein with mechanistic dissection via FGF21 knockout (dispensable), direct POMC neuron electrophysiology, and hepatic signaling assays; multiple orthogonal methods","pmids":["29515030"],"is_preprint":false},{"year":2018,"finding":"NOTCH1 signaling promotes ECM degradation during trabeculation while NRG1 promotes myocardial ECM synthesis, necessary for trabecular rearrangement and growth. NRG1 controls Vegfa expression, interconnecting the two systems that act antagonistically to establish trabecular architecture. These epistatic relationships were established using cardiac-specific mutant mouse models.","method":"Cardiac-specific mutant mouse models, confocal imaging, transcriptomic analysis, ECM quantification","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in multiple cardiac-specific mouse mutants with quantitative ECM and imaging readouts; published in high-impact journal with comprehensive mechanistic support","pmids":["29743679"],"is_preprint":false},{"year":2019,"finding":"NRG1/HER3 axis mediates ERBB3 activation by pancreatic cancer-associated fibroblasts (CAFs) and tumor cells; the anti-NRG1 antibody 7E3 blocks NRG1-mediated HER3 activation, promotes ADCC in NRG1-positive cells, and inhibits pancreatic cancer cell migration and growth co-cultured with CAFs both in vitro and in vivo in orthotopic xenografts.","method":"Anti-NRG1 antibody blocking, ADCC assays, co-culture migration/growth assays, orthotopic xenograft model","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody-mediated NRG1 blockade with receptor signaling and functional assays in vitro and in vivo; two orthogonal platforms","pmids":["29935372"],"is_preprint":false},{"year":2020,"finding":"Nedd4l (E3 ubiquitin ligase) ubiquitinates NRG1 in the medial prefrontal cortex (mPFC) of stress-susceptible mice, reducing NRG1 protein levels without changing mRNA. Overexpression of Nedd4l in mPFC decreases NRG1 and causes stress vulnerability; downregulation of Nedd4l rescues NRG1 levels and attenuates depression-like behaviors.","method":"Ubiquitination assay, viral vector-mediated overexpression/knockdown, chronic social defeat stress model, RNA sequencing","journal":"Translational psychiatry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ubiquitination assay identifies Nedd4l as E3 ligase for NRG1, confirmed by bidirectional in vivo manipulation (OE and KD) with behavioral and molecular phenotypes","pmids":["32703967"],"is_preprint":false},{"year":2021,"finding":"Dysfunctional ERBB3 or ERBB2 mutations (identified by trio-exome sequencing) cause reduced expression or altered phosphorylation of the mutant receptors (confirmed by RT-qPCR and immunoblot), leading to a developmental syndrome including HSCR, CIPO, peripheral neuropathy, and arthrogryposis. Single-cell RNA-seq and conditional ErbB3-deficient mouse models revealed a primary role for ERBB3 in enteric progenitors, establishing NRG1/ERBB3/ERBB2 signaling as essential for enteric nervous system development.","method":"Trio-exome sequencing, RT-qPCR on patient fibroblasts, immunoblot of mutant proteins, mouse scRNA-seq, conditional ErbB3 knockout mouse","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — human variant functional validation in patient cells plus conditional mouse model plus single-cell transcriptomics; multiple orthogonal methods converging on same pathway","pmids":["33497358"],"is_preprint":false},{"year":2021,"finding":"CAF-derived NRG1 activates cancer cell ERBB2 and ERBB3 receptor tyrosine kinases to support KRAS*-independent growth in PDAC. Genetic extinction or pharmacological inhibition of KRAS* upregulates ERBB2 and ERBB3 expression. Genetic depletion or pharmacological inhibition of ERBB2/3 or NRG1 abolishes KRAS* bypass and synergizes with KRASG12D inhibitors.","method":"Genetic depletion/pharmacologic inhibition of ERBB2/3 and NRG1 in mouse and human PDAC models, KRAS* extinction models, combination drug studies","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and pharmacologic approaches in both human and murine PDAC models; epistasis between KRAS* and NRG1/ERBB signaling established","pmids":["37775182"],"is_preprint":false},{"year":2021,"finding":"NRG1 regulates redox homeostasis in papillary thyroid cancer cells through the ERK pathway and NRF2, maintaining moderate ROS levels via ARE-containing antioxidant genes. NRG1 knockdown reduces cell viability and increases ROS, while NRG1 expression positively correlates with NRF2 in patient samples.","method":"NRG1 knockdown, ROS generation assay, intracellular GSH assay, Western blot for ERK/NRF2, CCK-8 assay","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional assays with loss-of-function in a single cell type; mechanistic pathway identified but single lab","pmids":["29901070"],"is_preprint":false},{"year":2022,"finding":"Zenocutuzumab (bispecific anti-HER2×HER3 antibody) blocks NRG1 binding to HER3, inhibiting HER3 and AKT phosphorylation, inducing apoptosis markers, and inhibiting growth in NRG1 fusion-positive isogenic and patient-derived cell lines and xenograft models. This establishes that NRG1 fusions signal through HER3-HER2 heterodimerization as the primary oncogenic mechanism.","method":"Bispecific antibody blocking, phospho-HER3/AKT assays, apoptosis assays, PDX xenograft models, clinical response in patients","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mechanistic antibody blocking targeting specific ligand-receptor interaction validated in isogenic cells, PDX models, and clinical setting; multiple orthogonal methods","pmids":["35135829"],"is_preprint":false},{"year":2022,"finding":"NRG1 fusions can stimulate downstream signaling through HER4 independently of other HER family members, and EGFR-HER3 signaling is also activated; pan-HER inhibition is more effective than selective HER2-HER3 targeting. Cetuximab (anti-EGFR) plus trastuzumab/pertuzumab (anti-HER2) yielded synergistic effects against NRG1 fusion-positive cells.","method":"Ba/F3 models engineered with individual HER family members plus NRG1 fusions, receptor phosphorylation assays, combination drug synergy assays, in vivo models","journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — isogenic Ba/F3 system with individual HER members plus NRG1 fusions directly tests receptor contribution; multiple drug combination studies in vitro and in vivo","pmids":["37678511"],"is_preprint":false},{"year":2022,"finding":"M2-like macrophage-derived Nrg1 signals through ErbB2 and ErbB4 on cardiac fibroblasts via PI3K/Akt pathway to suppress hydrogen peroxide-induced senescence and apoptosis of fibroblasts in infarcted myocardium. Blockade of ErbB function accelerates both fibroblast senescence/apoptosis and exacerbates inflammation. This Nrg1/ErbB/PI3K/Akt anti-senescence mechanism regulates post-MI fibrotic tissue formation.","method":"M2 macrophage isolation and co-culture, ErbB pharmacologic blockade, senescence/apoptosis assays, in vivo MI model with ErbB blockade","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic assays with in vivo validation; identifies macrophage as cellular source and establishes PI3K/Akt pathway mechanistically","pmids":["34997943"],"is_preprint":false},{"year":2022,"finding":"NRG1-ERBB3-mTORC2 signaling drives acinar specification in salivary glands: neuronal NRG1 activates epithelial ERBB3 to trigger lineage progression, secretion, and polarization of acinar progenitors via mTORC2. Genetic deletion of Erbb3 prevents acinar lineage progression and lumenized secretory acini formation; exogenous NRG1 treatment of isolated epithelia recapitulates acinar development.","method":"Single-cell RNA sequencing, Erbb3 conditional knockout, NRG1 treatment of isolated epithelia, mTORC2 pathway analysis","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic loss-of-function (conditional KO) plus gain-of-function (NRG1 treatment of isolated tissue) plus single-cell sequencing to define pathway; multiple orthogonal approaches","pmids":["36413949"],"is_preprint":false},{"year":2023,"finding":"Endocardial Nrg1 signals to myocardial ErbB2 to activate phospho-Erk, which regulates a transcriptional program for cardiomyocyte oriented cell division, trabeculation, and epithelial-to-mesenchymal transition-like migration. Loss of Nrg1 reduces cardiomyocyte Pard3 and Crumbs2 protein and alters cytoskeletal gene expression; ectopic Nrg1 overexpression causes S-phase arrest and prolonged trabeculation. Nrg1-dependent pErk activation controls Yap1 nuclear-cytoplasmic distribution.","method":"Cardiac-specific Nrg1 conditional knockout and overexpression mice, confocal imaging, transcriptomics, biochemical pErk/Yap1 assays","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — bidirectional genetic manipulation (KO + OE) with transcriptomics, imaging, and biochemical mechanistic validation of ErbB2-Erk-Yap1 pathway; multiple orthogonal methods","pmids":["37846569"],"is_preprint":false},{"year":2025,"finding":"Zenocutuzumab, a HER2×HER3 bispecific antibody that blocks NRG1 binding to HER3, produced objective responses in 30% of patients with NRG1 fusion-positive solid tumors across 12 tumor types, confirming that NRG1 fusions drive oncogenesis through HER3-HER2 heterodimerization as the primary mechanism.","method":"Phase 2 registrational clinical trial with objective response assessment","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — prospective registrational trial with 204 patients across 12 tumor types; mechanistic target (NRG1-HER3-HER2) validated at clinical scale","pmids":["39908431"],"is_preprint":false}],"current_model":"NRG1 (neuregulin-1) is a secreted/membrane-bound EGF-family ligand that binds primarily to ERBB3 (HER3) and ERBB4 (HER4), inducing heterodimerization with ERBB2 (HER2) — with ERBB2 serving as a co-receptor that decelerates ligand dissociation and amplifies signaling — thereby activating downstream PI3K/AKT, ERK/MAPK, and other cascades to regulate Schwann cell myelination, oligodendrocyte proliferation/differentiation, neuronal migration, cardiac trabeculation, and acinar specification, while oncogenic NRG1 gene fusions constitutively present the EGF-like domain on the cell surface, driving ERBB2-ERBB3/HER4-dependent tumorigenesis that is therapeutically targeted by the bispecific antibody zenocutuzumab."},"narrative":{"mechanistic_narrative":"NRG1 (neuregulin-1) is an EGF-family ligand that drives ErbB receptor tyrosine kinase signaling to control differentiation, proliferation, survival, and tissue morphogenesis across the nervous system, heart, and epithelia [PMID:8780647, PMID:29743679]. It binds with high affinity to ErbB3 and ErbB4 and induces receptor hetero-oligomerization into high-molecular-weight complexes, with ErbB2 (Neu/HER2) acting as a co-receptor that decelerates ligand dissociation and prolongs downstream activation of MAP kinase (ERK), SAPK/JNK, p38, and PI3K-coupled signaling [PMID:8096177, PMID:8045292, PMID:8617201, PMID:9400997]. NRG1 exists in multiple isoforms with distinct developmental and activity-dependent expression patterns, and type IV induction is CREB-dependent through a CRE element in its 5' UTR [PMID:21653853]. Through ErbB receptors, NRG1 functions as a mitogen and survival/differentiation regulator for oligodendrocyte progenitors and Schwann cells (the latter via an autocrine loop), governs radial glial maintenance and neuronal migration partly via brain lipid-binding protein, and shapes Pacinian corpuscle formation and enteric nervous system development through specific isoforms [PMID:8780647, PMID:9417836, PMID:9342043, PMID:27707970, PMID:33497358]. Peripheral myelination requires the PDZ protein Erbin, which stabilizes ErbB2 and sustains NRG1 signaling [PMID:19458253]. In the heart, endocardial/myocardial NRG1-ErbB2-ERK signaling controls cardiomyocyte oriented division, trabeculation, ECM synthesis, and Yap1 localization, acting antagonistically with NOTCH1 [PMID:29743679, PMID:37846569]. NRG1 also signals to GABAergic ErbB4-expressing interneurons to modulate inhibitory transmission and anxiety, a pathway antagonized by DISC1 and pharmacologically by spironolactone [PMID:25308353, PMID:26656849, PMID:28743784], and its abundance in the prefrontal cortex is controlled by Nedd4l-mediated ubiquitination in stress responses [PMID:32703967]. NRG1 drives oncogenesis: chromosomal fusions (CD74-NRG1, VAMP2-NRG1, and others) present the EGF-like domain to activate ERBB2-ERBB3 (and HER4/EGFR) heterodimers and the PI3K-AKT axis, promoting transformation, while paracrine NRG1 from cancer-associated fibroblasts sustains ERBB3-AKT signaling and confers therapy resistance [PMID:24469108, PMID:26134228, PMID:26837769, PMID:25952648, PMID:37775182]. NRG1 fusions signal primarily through HER3-HER2 heterodimerization, and the bispecific HER2×HER3 antibody zenocutuzumab blocks NRG1-HER3 binding and produces clinical responses across NRG1 fusion-positive tumors [PMID:35135829, PMID:39908431].","teleology":[{"year":1993,"claim":"Established that NRG1 (NDF) is a high-affinity ligand engaging Neu/HER2 plus an additional co-component and couples receptor activation to PI3-kinase, defining its receptor system.","evidence":"Radiolabeled NDF crosslinking, antibody blocking, and PI3K co-IP in mammary cells","pmids":["8096177"],"confidence":"High","gaps":["Identity of the additional co-receptor not resolved","Cell-type specificity of PI3K coupling unexplained"]},{"year":1994,"claim":"Identified ErbB3 as a direct NRG1 receptor whose engagement induces hetero-oligomerization, answering which receptor transduces the ligand signal.","evidence":"125I-NDF crosslinking, anti-ErbB3 immunoprecipitation, and tyrosine phosphorylation assays","pmids":["8045292"],"confidence":"High","gaps":["Composition of the >400 kDa complex not defined","Relative contributions of ErbB2 vs ErbB4 not yet dissected"]},{"year":1996,"claim":"Defined ErbB2's co-receptor mechanism, showing it decelerates ligand dissociation to prolong ERK/SAPK signaling, explaining how heterodimer composition tunes signal duration.","evidence":"Reciprocal co-IP, ER-trap intracellular antibody, ligand dissociation kinetics, and downstream kinase assays","pmids":["8617201"],"confidence":"High","gaps":["Structural basis of decelerated dissociation not shown","Quantitative link between signal duration and cell fate not established"]},{"year":1996,"claim":"Established NRG1 as a mitogen, survival, and differentiation-modulating factor for glial and neuronal lineages, defining its role in nervous system development.","evidence":"Oligodendrocyte/retinal cell proliferation, survival, and neurite assays with ErbB activation and antibody blocking","pmids":["8780647","8625831"],"confidence":"High","gaps":["Isoform responsible not resolved","In vivo relevance of differentiation inhibition incomplete"]},{"year":1997,"claim":"Connected NRG1 to cortical development and Schwann cell biology, showing it drives radial glial maintenance/neuronal migration and an autocrine Schwann cell proliferative loop.","evidence":"In vitro migration assays, ErbB2-deficient mice, BLBP analysis, ELISA secretion detection, and antibody neutralization","pmids":["9342043","9417836","9419971"],"confidence":"High","gaps":["Mechanism of BLBP induction downstream of NRG1 not detailed","Isoform-specific autocrine signaling not yet dissected"]},{"year":2011,"claim":"Defined NRG1 isoform diversity and activity-dependent transcriptional control, showing type IV induction is CREB-mediated, explaining how neuronal activity regulates ligand availability.","evidence":"Isoform-specific qPCR, in situ hybridization, and CRE reporter/CREB binding analysis","pmids":["21653853"],"confidence":"Medium","gaps":["Functional consequences of activity-induced isoforms in vivo not established","Regulation of other isoforms incompletely defined"]},{"year":2009,"claim":"Identified Erbin as an essential cofactor that stabilizes ErbB2 to enable NRG1-dependent peripheral myelination, revealing a structural requirement for signaling.","evidence":"Erbin-null and PDZ-deletion knockin mice, ErbB2 stability assays, Erbin-ErbB2 co-IP, and nerve conduction measurements","pmids":["19458253"],"confidence":"High","gaps":["How Erbin biochemically stabilizes ErbB2 not fully resolved","Generalization beyond peripheral nerve untested"]},{"year":2014,"claim":"Placed NRG1-ErbB4 signaling in GABAergic interneuron circuits and linked it to TrkB/BDNF and NMDA receptor regulation, defining its neuromodulatory role.","evidence":"Co-IP/PLA of TrkB-ErbB4, TrkB knockout/siRNA, pharmacology, BDNF neutralization, BLA electrophysiology and behavior","pmids":["25052836","25308353"],"confidence":"High","gaps":["Direct ErbB4-TrkB binding interface not mapped","Behavioral circuit specificity incompletely defined"]},{"year":2015,"claim":"Showed DISC1 antagonizes NRG1-ErbB4 signaling via competition for PSD95 binding, providing a mechanistic node linking the pathway to interneuron circuit phenotypes.","evidence":"Cell-type-specific DISC1 modulation, mutant DISC1 knockin mice, ErbB4/PSD95 binding competition, electrophysiology","pmids":["26656849"],"confidence":"High","gaps":["Stoichiometry of DISC1-ErbB4-PSD95 competition unresolved","Disease relevance not directly tested"]},{"year":2014,"claim":"Demonstrated that NRG1 gene fusions (CD74-NRG1) present the EGF-like domain extracellularly to activate ERBB2-ERBB3 and PI3K-AKT, establishing NRG1 as an oncogenic driver.","evidence":"Transcriptome sequencing, ectopic fusion expression, phospho-receptor assays, and soft agar colony formation","pmids":["24469108"],"confidence":"High","gaps":["Range of partner genes not fully cataloged","Therapeutic targeting not yet defined at this stage"]},{"year":2015,"claim":"Extended NRG1 fusion biology to additional partners and downstream circuits, including VAMP2-NRG1 membrane display and CD74-NRG1-driven NF-κB/IGF2 autocrine stemness.","evidence":"Ectopic fusion expression, phospho-signaling, sphere/colony formation, xenografts, and pharmacologic pathway dissection","pmids":["26134228","26837769"],"confidence":"High","gaps":["Generality of IGF2 circuit across fusion types untested","Relative oncogenic potency of different fusions not compared"]},{"year":2021,"claim":"Established paracrine NRG1 from cancer-associated fibroblasts as a driver of ERBB3-AKT signaling and KRAS-bypass/therapy resistance, defining a stromal source of pathway activation.","evidence":"Conditioned medium, genetic/pharmacologic ERBB2/3 and NRG1 inhibition in human and murine PDAC and uveal melanoma models","pmids":["25952648","37775182","29935372"],"confidence":"High","gaps":["Triggers of CAF NRG1 secretion not defined","Clinical translatability of stromal targeting incompletely tested"]},{"year":2018,"claim":"Defined NRG1-ErbB roles in organ morphogenesis and metabolism, including cardiac trabeculation/ECM synthesis, salivary acinar specification via mTORC2, and central metabolic control via POMC neurons.","evidence":"Cardiac-specific mutant mice, Erbb3 conditional KO with NRG1 epithelial treatment, scRNA-seq, and engineered NRG1-Fc with POMC electrophysiology","pmids":["29743679","37846569","36413949","29515030"],"confidence":"High","gaps":["Isoform/receptor selectivity across these tissues not unified","Direct receptor identity for hypothalamic effect not fully resolved"]},{"year":2021,"claim":"Provided human genetic and developmental evidence that NRG1/ERBB3/ERBB2 signaling is essential for enteric nervous system and peripheral neural development, linking the pathway to a Mendelian developmental syndrome.","evidence":"Trio-exome sequencing, patient fibroblast RT-qPCR/immunoblot, mouse scRNA-seq, and conditional ErbB3 knockout","pmids":["33497358"],"confidence":"High","gaps":["Pathogenic NRG1 variants (vs ERBB3/2) not directly demonstrated here","Genotype-phenotype range incompletely defined"]},{"year":2020,"claim":"Identified Nedd4l as the E3 ligase controlling NRG1 protein abundance post-translationally in the prefrontal cortex, linking ligand turnover to stress susceptibility.","evidence":"Ubiquitination assay and bidirectional viral Nedd4l manipulation in a chronic social defeat stress model","pmids":["32703967"],"confidence":"High","gaps":["Ubiquitination site on NRG1 not mapped","Whether this regulates secreted vs membrane NRG1 unclear"]},{"year":2025,"claim":"Validated HER3-HER2 heterodimerization as the primary oncogenic mechanism of NRG1 fusions by demonstrating clinical efficacy of zenocutuzumab, which blocks NRG1-HER3 binding.","evidence":"Bispecific antibody mechanistic assays in isogenic/PDX models plus a Phase 2 registrational trial across 12 tumor types","pmids":["35135829","39908431","37678511"],"confidence":"High","gaps":["Resistance mechanisms (HER4/EGFR contributions) require fuller dissection","Predictors of the ~30% response rate not defined"]},{"year":null,"claim":"How distinct NRG1 isoforms, membrane vs secreted forms, and receptor heterodimer combinations are matched to specific cellular outcomes across tissues remains incompletely defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model linking isoform to receptor heterodimer selectivity","Quantitative rules relating signal duration to fate decisions absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,3,16]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,3,8]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[16,23]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[9,13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,8,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,28,37,38]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[16,19,32,34,39]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[4,18,20]}],"complexes":[],"partners":["ERBB3","ERBB2","ERBB4","ERBB1","ERBIN","NEDD4L"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q02297","full_name":"Pro-neuregulin-1, membrane-bound isoform","aliases":[],"length_aa":640,"mass_kda":70.4,"function":"Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. The multiple isoforms perform diverse functions such as inducing growth and differentiation of epithelial, glial, neuronal, and skeletal muscle cells; inducing expression of acetylcholine receptor in synaptic vesicles during the formation of the neuromuscular junction; stimulating lobuloalveolar budding and milk production in the mammary gland and inducing differentiation of mammary tumor cells; stimulating Schwann cell proliferation; implication in the development of the myocardium such as trabeculation of the developing heart. Isoform 10 may play a role in motor and sensory neuron development. Binds to ERBB4 (PubMed:10867024, PubMed:7902537). Binds to ERBB3 (PubMed:20682778). Acts as a ligand for integrins and binds (via EGF domain) to integrins ITGAV:ITGB3 or ITGA6:ITGB4. Its binding to integrins and subsequent ternary complex formation with integrins and ERRB3 are essential for NRG1-ERBB signaling. Induces the phosphorylation and activation of MAPK3/ERK1, MAPK1/ERK2 and AKT1 (PubMed:20682778). Ligand-dependent ERBB4 endocytosis is essential for the NRG1-mediated activation of these kinases in neurons (By similarity)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q02297/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NRG1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NRG1","total_profiled":1310},"omim":[{"mim_id":"619465","title":"VISCERAL NEUROPATHY, FAMILIAL, 2, AUTOSOMAL RECESSIVE; VSCN2","url":"https://www.omim.org/entry/619465"},{"mim_id":"615515","title":"AMYOTROPHIC LATERAL SCLEROSIS 19; ALS19","url":"https://www.omim.org/entry/615515"},{"mim_id":"611945","title":"SPASTIC PARAPLEGIA 37, AUTOSOMAL DOMINANT; SPG37","url":"https://www.omim.org/entry/611945"},{"mim_id":"610894","title":"NEUREGULIN 4; NRG4","url":"https://www.omim.org/entry/610894"},{"mim_id":"608984","title":"ATAXIA, SENSORY, 1, AUTOSOMAL DOMINANT; SNAX1","url":"https://www.omim.org/entry/608984"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":15.9}],"url":"https://www.proteinatlas.org/search/NRG1"},"hgnc":{"alias_symbol":["HRG","NDF","GGF"],"prev_symbol":["HGL","NRG1-IT2"]},"alphafold":{"accession":"Q02297","domains":[{"cath_id":"2.60.40.10","chopping":"40-131","consensus_level":"high","plddt":91.7151,"start":40,"end":131},{"cath_id":"2.10.25.10","chopping":"180-228","consensus_level":"high","plddt":80.6014,"start":180,"end":228},{"cath_id":"1.20.5","chopping":"230-287","consensus_level":"medium","plddt":87.8026,"start":230,"end":287}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02297","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q02297-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q02297-F1-predicted_aligned_error_v6.png","plddt_mean":56.66},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NRG1","jax_strain_url":"https://www.jax.org/strain/search?query=NRG1"},"sequence":{"accession":"Q02297","fasta_url":"https://rest.uniprot.org/uniprotkb/Q02297.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q02297/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02297"}},"corpus_meta":[{"pmid":"8617201","id":"PMC_8617201","title":"ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8617201","citation_count":561,"is_preprint":false},{"pmid":"8780647","id":"PMC_8780647","title":"GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors.","date":"1996","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/8780647","citation_count":322,"is_preprint":false},{"pmid":"9342043","id":"PMC_9342043","title":"Role of GGF/neuregulin signaling in interactions between migrating neurons and radial glia in the developing cerebral cortex.","date":"1997","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9342043","citation_count":287,"is_preprint":false},{"pmid":"24469108","id":"PMC_24469108","title":"CD74-NRG1 fusions in lung adenocarcinoma.","date":"2014","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/24469108","citation_count":238,"is_preprint":false},{"pmid":"8096177","id":"PMC_8096177","title":"Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.","date":"1993","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8096177","citation_count":229,"is_preprint":false},{"pmid":"31311833","id":"PMC_31311833","title":"A Coevolved EDS1-SAG101-NRG1 Module Mediates Cell Death Signaling by TIR-Domain Immune Receptors.","date":"2019","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/31311833","citation_count":224,"is_preprint":false},{"pmid":"20832498","id":"PMC_20832498","title":"Nrg1/ErbB signaling networks in Schwann cell development and myelination.","date":"2010","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20832498","citation_count":205,"is_preprint":false},{"pmid":"29802158","id":"PMC_29802158","title":"NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.","date":"2018","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29802158","citation_count":200,"is_preprint":false},{"pmid":"30582759","id":"PMC_30582759","title":"Diverse NLR immune receptors activate defence via the RPW8-NLR NRG1.","date":"2019","source":"The New phytologist","url":"https://pubmed.ncbi.nlm.nih.gov/30582759","citation_count":193,"is_preprint":false},{"pmid":"30988082","id":"PMC_30988082","title":"Detection of NRG1 Gene Fusions in Solid Tumors.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30988082","citation_count":184,"is_preprint":false},{"pmid":"12024013","id":"PMC_12024013","title":"Snf1 protein kinase and the repressors Nrg1 and Nrg2 regulate FLO11, haploid invasive growth, and diploid pseudohyphal differentiation.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12024013","citation_count":174,"is_preprint":false},{"pmid":"16520822","id":"PMC_16520822","title":"Association of the NRG1 gene and schizophrenia: a meta-analysis.","date":"2006","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/16520822","citation_count":173,"is_preprint":false},{"pmid":"29743679","id":"PMC_29743679","title":"Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29743679","citation_count":169,"is_preprint":false},{"pmid":"35135829","id":"PMC_35135829","title":"Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.","date":"2022","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35135829","citation_count":146,"is_preprint":false},{"pmid":"25531467","id":"PMC_25531467","title":"Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25531467","citation_count":137,"is_preprint":false},{"pmid":"34099661","id":"PMC_34099661","title":"Pathogen effector recognition-dependent association of NRG1 with EDS1 and SAG101 in TNL receptor immunity.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34099661","citation_count":137,"is_preprint":false},{"pmid":"21653853","id":"PMC_21653853","title":"Specific regulation of NRG1 isoform expression by neuronal activity.","date":"2011","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21653853","citation_count":136,"is_preprint":false},{"pmid":"32916265","id":"PMC_32916265","title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.","date":"2020","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32916265","citation_count":134,"is_preprint":false},{"pmid":"31068372","id":"PMC_31068372","title":"NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31068372","citation_count":131,"is_preprint":false},{"pmid":"9400997","id":"PMC_9400997","title":"ErbB kinases and NDF signaling in human prostate cancer cells.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9400997","citation_count":128,"is_preprint":false},{"pmid":"7824269","id":"PMC_7824269","title":"NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7824269","citation_count":112,"is_preprint":false},{"pmid":"9419971","id":"PMC_9419971","title":"Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9419971","citation_count":107,"is_preprint":false},{"pmid":"8625831","id":"PMC_8625831","title":"Effects of GGF/neuregulins on neuronal survival and neurite outgrowth correlate with erbB2/neu expression in developing rat retina.","date":"1996","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8625831","citation_count":107,"is_preprint":false},{"pmid":"39908431","id":"PMC_39908431","title":"Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.","date":"2025","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39908431","citation_count":90,"is_preprint":false},{"pmid":"10192767","id":"PMC_10192767","title":"GGF/neuregulin induces a phenotypic reversion of oligodendrocytes.","date":"1999","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/10192767","citation_count":88,"is_preprint":false},{"pmid":"25501131","id":"PMC_25501131","title":"Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25501131","citation_count":77,"is_preprint":false},{"pmid":"19659570","id":"PMC_19659570","title":"NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.","date":"2009","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/19659570","citation_count":71,"is_preprint":false},{"pmid":"8045292","id":"PMC_8045292","title":"NDF/heregulin stimulates the phosphorylation of Her3/erbB3.","date":"1994","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8045292","citation_count":70,"is_preprint":false},{"pmid":"25308353","id":"PMC_25308353","title":"Amygdala NRG1-ErbB4 is critical for the modulation of anxiety-like behaviors.","date":"2014","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25308353","citation_count":69,"is_preprint":false},{"pmid":"25996292","id":"PMC_25996292","title":"Activation of NRG1-ERBB4 signaling potentiates mesenchymal stem cell-mediated myocardial repairs following myocardial infarction.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25996292","citation_count":67,"is_preprint":false},{"pmid":"9417836","id":"PMC_9417836","title":"Schwann cells express NDF and SMDF/n-ARIA mRNAs, secrete neuregulin, and show constitutive activation of erbB3 receptors: evidence for a neuregulin autocrine loop.","date":"1997","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9417836","citation_count":65,"is_preprint":false},{"pmid":"19458253","id":"PMC_19458253","title":"Erbin regulates NRG1 signaling and myelination.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19458253","citation_count":64,"is_preprint":false},{"pmid":"31382039","id":"PMC_31382039","title":"Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.","date":"2019","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31382039","citation_count":61,"is_preprint":false},{"pmid":"16019744","id":"PMC_16019744","title":"Composite PHB-GGF conduit for long nerve gap repair: a long-term evaluation.","date":"2005","source":"Scandinavian journal of plastic and reconstructive surgery and hand surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16019744","citation_count":60,"is_preprint":false},{"pmid":"16278455","id":"PMC_16278455","title":"Repressors Nrg1 and Nrg2 regulate a set of stress-responsive genes in Saccharomyces cerevisiae.","date":"2005","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/16278455","citation_count":60,"is_preprint":false},{"pmid":"25952648","id":"PMC_25952648","title":"Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25952648","citation_count":59,"is_preprint":false},{"pmid":"26656849","id":"PMC_26656849","title":"Interneuronal DISC1 regulates NRG1-ErbB4 signalling and excitatory-inhibitory synapse formation in the mature cortex.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26656849","citation_count":59,"is_preprint":false},{"pmid":"28951744","id":"PMC_28951744","title":"IGF1 and NRG1 Enhance Proliferation, Metabolic Maturity, and the Force-Frequency Response in hESC-Derived Engineered Cardiac Tissues.","date":"2017","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/28951744","citation_count":58,"is_preprint":false},{"pmid":"26837769","id":"PMC_26837769","title":"Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26837769","citation_count":57,"is_preprint":false},{"pmid":"31607147","id":"PMC_31607147","title":"Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure.","date":"2019","source":"Circulation. Heart failure","url":"https://pubmed.ncbi.nlm.nih.gov/31607147","citation_count":54,"is_preprint":false},{"pmid":"21047912","id":"PMC_21047912","title":"LH-induced neuregulin 1 (NRG1) type III transcripts control granulosa cell differentiation and oocyte maturation.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21047912","citation_count":54,"is_preprint":false},{"pmid":"32852072","id":"PMC_32852072","title":"Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.","date":"2020","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/32852072","citation_count":50,"is_preprint":false},{"pmid":"9775980","id":"PMC_9775980","title":"Chronically denervated rat Schwann cells respond to GGF in vitro.","date":"1998","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/9775980","citation_count":47,"is_preprint":false},{"pmid":"29935372","id":"PMC_29935372","title":"Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29935372","citation_count":47,"is_preprint":false},{"pmid":"34996744","id":"PMC_34996744","title":"NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis.","date":"2022","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34996744","citation_count":44,"is_preprint":false},{"pmid":"23400839","id":"PMC_23400839","title":"RET and NRG1 interplay in Hirschsprung disease.","date":"2013","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23400839","citation_count":41,"is_preprint":false},{"pmid":"38348690","id":"PMC_38348690","title":"The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.","date":"2024","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38348690","citation_count":39,"is_preprint":false},{"pmid":"34997943","id":"PMC_34997943","title":"Nrg1/ErbB signaling-mediated regulation of fibrosis after myocardial infarction.","date":"2022","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34997943","citation_count":39,"is_preprint":false},{"pmid":"29515030","id":"PMC_29515030","title":"NRG1-Fc improves metabolic health via dual hepatic and central action.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29515030","citation_count":38,"is_preprint":false},{"pmid":"37846569","id":"PMC_37846569","title":"Nrg1 Regulates Cardiomyocyte Migration and Cell Cycle in Ventricular Development.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/37846569","citation_count":36,"is_preprint":false},{"pmid":"29759984","id":"PMC_29759984","title":"NDF, a nucleosome-destabilizing factor that facilitates transcription through nucleosomes.","date":"2018","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/29759984","citation_count":36,"is_preprint":false},{"pmid":"28743784","id":"PMC_28743784","title":"Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice.","date":"2017","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28743784","citation_count":36,"is_preprint":false},{"pmid":"28573357","id":"PMC_28573357","title":"Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.","date":"2017","source":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","url":"https://pubmed.ncbi.nlm.nih.gov/28573357","citation_count":36,"is_preprint":false},{"pmid":"26134228","id":"PMC_26134228","title":"VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.","date":"2015","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26134228","citation_count":35,"is_preprint":false},{"pmid":"33497358","id":"PMC_33497358","title":"Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33497358","citation_count":33,"is_preprint":false},{"pmid":"32618511","id":"PMC_32618511","title":"The role of endothelial autocrine NRG1/ERBB4 signaling in cardiac remodeling.","date":"2020","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32618511","citation_count":33,"is_preprint":false},{"pmid":"19439994","id":"PMC_19439994","title":"DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study.","date":"2009","source":"Neuropsychobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19439994","citation_count":32,"is_preprint":false},{"pmid":"32690068","id":"PMC_32690068","title":"CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.","date":"2020","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32690068","citation_count":31,"is_preprint":false},{"pmid":"29607874","id":"PMC_29607874","title":"Astraglaus polysaccharide protects diabetic cardiomyopathy by activating NRG1/ErbB pathway.","date":"2018","source":"Bioscience trends","url":"https://pubmed.ncbi.nlm.nih.gov/29607874","citation_count":31,"is_preprint":false},{"pmid":"29225331","id":"PMC_29225331","title":"Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients.","date":"2017","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29225331","citation_count":30,"is_preprint":false},{"pmid":"35876932","id":"PMC_35876932","title":"Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats.","date":"2022","source":"Inflammopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35876932","citation_count":30,"is_preprint":false},{"pmid":"36259930","id":"PMC_36259930","title":"Effector XopQ-induced stromule formation in Nicotiana benthamiana depends on ETI signaling components ADR1 and NRG1.","date":"2023","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36259930","citation_count":30,"is_preprint":false},{"pmid":"34486669","id":"PMC_34486669","title":"Prrx1b restricts fibrosis and promotes Nrg1-dependent cardiomyocyte proliferation during zebrafish heart regeneration.","date":"2021","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34486669","citation_count":29,"is_preprint":false},{"pmid":"28901268","id":"PMC_28901268","title":"NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?","date":"2017","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28901268","citation_count":28,"is_preprint":false},{"pmid":"28273943","id":"PMC_28273943","title":"Increased NRG1-ErbB4 signaling in human symptomatic epilepsy.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28273943","citation_count":28,"is_preprint":false},{"pmid":"34680187","id":"PMC_34680187","title":"Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34680187","citation_count":28,"is_preprint":false},{"pmid":"35370955","id":"PMC_35370955","title":"MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35370955","citation_count":28,"is_preprint":false},{"pmid":"27707970","id":"PMC_27707970","title":"A RET-ER81-NRG1 Signaling Pathway Drives the Development of Pacinian Corpuscles.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27707970","citation_count":27,"is_preprint":false},{"pmid":"28857490","id":"PMC_28857490","title":"The acceleration of reproductive aging in Nrg1flox/flox ;Cyp19-Cre female mice.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/28857490","citation_count":27,"is_preprint":false},{"pmid":"34992218","id":"PMC_34992218","title":"NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34992218","citation_count":26,"is_preprint":false},{"pmid":"29121253","id":"PMC_29121253","title":"The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma.","date":"2018","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29121253","citation_count":24,"is_preprint":false},{"pmid":"33413557","id":"PMC_33413557","title":"NRG1 fusions in breast cancer.","date":"2021","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/33413557","citation_count":23,"is_preprint":false},{"pmid":"37775182","id":"PMC_37775182","title":"Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer.","date":"2023","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/37775182","citation_count":22,"is_preprint":false},{"pmid":"32703967","id":"PMC_32703967","title":"Nedd4l downregulation of NRG1 in the mPFC induces depression-like behaviour in CSDS mice.","date":"2020","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32703967","citation_count":22,"is_preprint":false},{"pmid":"33692466","id":"PMC_33692466","title":"Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33692466","citation_count":21,"is_preprint":false},{"pmid":"34732706","id":"PMC_34732706","title":"NRG1/ErbB signalling controls the dialogue between macrophages and neural crest-derived cells during zebrafish fin regeneration.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34732706","citation_count":21,"is_preprint":false},{"pmid":"30662268","id":"PMC_30662268","title":"lncRNA CASC9 regulates cell migration and invasion in hemangioma endothelial cells by targeting miR-125a-3p/Nrg1.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30662268","citation_count":21,"is_preprint":false},{"pmid":"34098222","id":"PMC_34098222","title":"NRG1 fusions: Biology to therapy.","date":"2021","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/34098222","citation_count":20,"is_preprint":false},{"pmid":"9621956","id":"PMC_9621956","title":"Predicting forage indigestible NDF from lignin concentration.","date":"1998","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/9621956","citation_count":20,"is_preprint":false},{"pmid":"38175774","id":"PMC_38175774","title":"Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38175774","citation_count":19,"is_preprint":false},{"pmid":"32828943","id":"PMC_32828943","title":"Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1/NRG1 pathway.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32828943","citation_count":19,"is_preprint":false},{"pmid":"37678511","id":"PMC_37678511","title":"HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.","date":"2023","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37678511","citation_count":18,"is_preprint":false},{"pmid":"21364580","id":"PMC_21364580","title":"Expression of NRG1 and its receptors in human bladder cancer.","date":"2011","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21364580","citation_count":18,"is_preprint":false},{"pmid":"31583038","id":"PMC_31583038","title":"Nrg1 Intracellular Signaling Is Neuroprotective upon Stroke.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/31583038","citation_count":18,"is_preprint":false},{"pmid":"33541789","id":"PMC_33541789","title":"Roles and mechanisms of NRG1 in modulating the pathogenesis of NAFLD through ErbB3 signaling in hepatocytes (NRG1 modulates NAFLD through ErbB3 signaling).","date":"2021","source":"Obesity research & clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/33541789","citation_count":18,"is_preprint":false},{"pmid":"25052836","id":"PMC_25052836","title":"TrkB interacts with ErbB4 and regulates NRG1-induced NR2B phosphorylation in cortical neurons before synaptogenesis.","date":"2014","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/25052836","citation_count":18,"is_preprint":false},{"pmid":"14672197","id":"PMC_14672197","title":"Effects of corn silage hybrid and dietary concentration of forage NDF on digestibility and performance by dairy cows.","date":"2003","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/14672197","citation_count":17,"is_preprint":false},{"pmid":"31685488","id":"PMC_31685488","title":"MCLA-128 Fights NRG1 Fusion-Positive Cancers.","date":"2019","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/31685488","citation_count":17,"is_preprint":false},{"pmid":"35247506","id":"PMC_35247506","title":"Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities.","date":"2022","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35247506","citation_count":16,"is_preprint":false},{"pmid":"22974608","id":"PMC_22974608","title":"Aberrant high expression of NRG1 gene in Hirschsprung disease.","date":"2012","source":"Journal of pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/22974608","citation_count":16,"is_preprint":false},{"pmid":"39874927","id":"PMC_39874927","title":"The UCP2/PINK1/LC3b-mediated mitophagy is involved in the protection of NRG1 against myocardial ischemia/reperfusion injury.","date":"2025","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/39874927","citation_count":15,"is_preprint":false},{"pmid":"30180823","id":"PMC_30180823","title":"NRG1 variant effects in patients with Hirschsprung disease.","date":"2018","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/30180823","citation_count":15,"is_preprint":false},{"pmid":"35406375","id":"PMC_35406375","title":"NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35406375","citation_count":15,"is_preprint":false},{"pmid":"34023356","id":"PMC_34023356","title":"NFKB2 inhibits NRG1 transcription to affect nucleus pulposus cell degeneration and inflammation in intervertebral disc degeneration.","date":"2021","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/34023356","citation_count":15,"is_preprint":false},{"pmid":"29901070","id":"PMC_29901070","title":"NRG1 regulates redox homeostasis via NRF2 in papillary thyroid cancer.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29901070","citation_count":15,"is_preprint":false},{"pmid":"26534905","id":"PMC_26534905","title":"Polymorphisms of dopamine pathway genes NRG1 and LMX1A are associated with cognitive performance in bipolar disorder.","date":"2015","source":"Bipolar disorders","url":"https://pubmed.ncbi.nlm.nih.gov/26534905","citation_count":15,"is_preprint":false},{"pmid":"23690216","id":"PMC_23690216","title":"The expression and localization of neuregulin-1 (Nrg1) in the gastrointestinal system of the rhesus monkey.","date":"2013","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/23690216","citation_count":14,"is_preprint":false},{"pmid":"36413949","id":"PMC_36413949","title":"Neuronal-epithelial cross-talk drives acinar specification via NRG1-ERBB3-mTORC2 signaling.","date":"2022","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/36413949","citation_count":14,"is_preprint":false},{"pmid":"25159022","id":"PMC_25159022","title":"NRG1-ErbB signalling promotes microglia activation contributing to incision-induced mechanical allodynia.","date":"2014","source":"European journal of pain (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25159022","citation_count":14,"is_preprint":false},{"pmid":"37164276","id":"PMC_37164276","title":"RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.","date":"2023","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/37164276","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53184,"output_tokens":10853,"usd":0.161173,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21553,"output_tokens":5314,"usd":0.120307,"stage2_stop_reason":"end_turn"},"total_usd":0.28148,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"NDF (NRG1) binds with high affinity (Kd ~10^-9 M) to mammary cells via Neu/HER-2 and an additional cellular co-component; direct radiolabeled cross-linking showed covalent association with Neu in breast but not ovarian cells, and NDF-induced Neu activation was coupled to PI3-kinase association in a cell-type-specific manner.\",\n      \"method\": \"Radiolabeled NDF cross-linking, monoclonal antibody blocking, direct binding analysis, PI3K co-immunoprecipitation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct binding assay with Kd measurement, covalent crosslinking, and PI3K co-IP; multiple orthogonal methods in one study\",\n      \"pmids\": [\"8096177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"NDF (NRG1) stimulates tyrosine phosphorylation of Her3/ErbB3, and chemical crosslinking of radiolabeled NDF to cells immunoprecipitated with anti-Her3 reveals a high-molecular-weight complex (>400 kDa), indicating NDF is a ligand for ErbB3 that induces receptor hetero-oligomerization.\",\n      \"method\": \"Tyrosine phosphorylation assay, 125I-NDF crosslinking, immunoprecipitation\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — radiolabeled ligand crosslinking plus immunoprecipitation and phosphorylation assay; two orthogonal methods establishing ErbB3 as NDF receptor\",\n      \"pmids\": [\"8045292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"NDF (NRG1) activates MAP kinase (p44ERK1/p42ERK2) and p70/p85 S6 kinase, and stimulates tyrosine phosphorylation and in vitro kinase activity of ErbB-2 in mammary epithelial cells; PKC activation by TPA blocks NDF-induced ErbB-2 activation and cell proliferation.\",\n      \"method\": \"In vitro kinase assay, MAP kinase activation assay, TPA-mediated PKC activation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay plus pathway activation assays with pharmacologic perturbation across multiple cell lines\",\n      \"pmids\": [\"7824269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"ErbB-2 forms heterodimers with EGF receptor (ErbB-1) and NDF receptors (ErbB-3 and ErbB-4); ErbB-2 overexpression enhances binding affinity to NDF by decelerating ligand dissociation, while ER-trapped anti-ErbB-2 antibody removes ErbB-2 from cell surface and almost completely abolishes NDF binding by accelerating dissociation. These kinetic effects prolong MAP kinase (ERK) and c-Jun kinase (SAPK) activation.\",\n      \"method\": \"Co-immunoprecipitation of heterodimers, intracellular antibody (ER-trap) blocking, ligand dissociation kinetics, ERK/SAPK activation assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reciprocal co-IP, gain- and loss-of-function (overexpression + ER-trap antibody), ligand kinetics, and downstream signaling; multiple orthogonal methods replicated across cell types\",\n      \"pmids\": [\"8617201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GGF/neuregulin (NRG1) acts as a mitogen and survival factor for oligodendrocyte progenitors (O4+/O1- cells) and oligodendrocytes; high GGF levels reversibly inhibit differentiation and lineage commitment. GGF activates all three ErbB receptors expressed by progenitors (ErbB2, ErbB3, ErbB4). Cortical neurons release a soluble GGF-like mitogen for pro-oligodendrocytes that is blocked by anti-GGF antibodies.\",\n      \"method\": \"Cell proliferation/survival assays, ErbB receptor activation assays, antibody blocking of conditioned medium\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional cell assays with receptor activation measurement and antibody blocking; multiple orthogonal experiments in a single study\",\n      \"pmids\": [\"8780647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GGF/neuregulin (NRG1) promotes survival and neurite extension from embryonic and neonatal rat retinal neurons in a dose-dependent manner, with effects correlating with erbB2/neu expression levels during retinal development.\",\n      \"method\": \"Dissociated retinal cell cultures, neuronal survival and neurite outgrowth assays, receptor expression analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional assays with dose-response and receptor correlation; single lab, single cell-type system\",\n      \"pmids\": [\"8625831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"GGF (NRG1) promotes neuronal migration along radial glial fibers and maintenance/elongation of radial glial cells during cortical development; loss of GGF signaling via ErbB2 receptors causes abnormal radial glial development. GGF's regulation of radial glia is mediated in part through brain lipid-binding protein (BLBP).\",\n      \"method\": \"In vitro neuronal migration assays, ErbB2-deficient mouse models, BLBP expression analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function genetic model plus in vitro functional assays identifying BLBP as downstream mediator; two orthogonal approaches\",\n      \"pmids\": [\"9342043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ErbB-3 (NDF/NRG1 receptor) is expressed primarily in epithelial layers, peripheral nervous system, and adult brain; ErbB-4 is restricted to developing CNS and embryonic heart. Blocking endogenous NDF with soluble ErbB-4 accelerated neurite outgrowth in primary brain cultures and P19 teratocarcinoma, demonstrating an inhibitory role of NDF on neural differentiation. ErbB-3 is associated with proliferation while ErbB-4 correlates with differentiated phenotype in P19 cells.\",\n      \"method\": \"Soluble receptor blocking, primary brain culture neurite outgrowth assay, P19 differentiation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — soluble receptor blocking with functional readout (neurite outgrowth) plus receptor-phenotype correlation; two orthogonal approaches\",\n      \"pmids\": [\"9419971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NDF/NRG1 activates ErbB3-ErbB2 crosstalk in LNCaP prostate cells without involving ErbB1; NDF activates PI3K (forming an 'activation complex' with ErbB3), ERK/MAPK, mHOG/p38, and JNK/SAPK pathways, but not PLCγ or STAT family signaling, demonstrating a distinct signaling pattern from TGF-α.\",\n      \"method\": \"Tyrosine phosphorylation assays, PI3K co-immunoprecipitation, pathway activation assays in prostate cell lines\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple pathway assays in a single cell line model; comprehensive but single lab\",\n      \"pmids\": [\"9400997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Schwann cells secrete a ~45 kDa neuregulin protein (NRG1) and show constitutive activation of ErbB3, indicating an autocrine loop. Anti-neuregulin antibody inhibited Schwann cell proliferation stimulated by neurons and by multiple unrelated mitogens (bFGF, HGF, TGF-β1), implicating NRG1 autocrine signaling in Schwann cell mitogenic responses.\",\n      \"method\": \"ELISA detection of secreted neuregulin, ErbB3 phosphorylation assays, antibody neutralization of proliferation assays\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — secretion detection plus constitutive receptor activation plus antibody neutralization functional assay; multiple orthogonal methods\",\n      \"pmids\": [\"9417836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"GGF/NRG1 induces phenotypic reversion of differentiated oligodendrocytes: loss of MBP expression, re-expression of nestin, reorganization of actin cytoskeleton, and reduction in process number. GGF is not cytotoxic but enhances survival. GGF rapidly activates PI3-kinase and MAP kinase signaling pathways in oligodendrocytes.\",\n      \"method\": \"TUNEL assay, immunostaining for MBP/nestin, PI3K and MAPK activation assays\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple phenotypic readouts with parallel pathway activation assays; functional consequence clearly tied to signaling\",\n      \"pmids\": [\"10192767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Erbin, a PDZ domain protein that interacts specifically with ErbB2, is required for NRG1 signaling and myelination of the peripheral nervous system. Erbin stabilizes ErbB2 protein; loss of the Erbin PDZ domain causes ErbB2 instability and compromised NRG1 signaling. Erbin null mice and erbin(DeltaC/DeltaC) mice show hypomyelination, aberrant Remak bundle formation, reduced nerve conduction velocity, and sensory threshold changes.\",\n      \"method\": \"Genetic knockout/knock-in mouse models, ErbB2 protein stability assays, nerve conduction velocity measurement, co-immunoprecipitation of Erbin-ErbB2\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (null + PDZ-deletion knockin) with mechanistic follow-up (ErbB2 stabilization by Erbin-ErbB2 interaction) and functional phenotypic readouts\",\n      \"pmids\": [\"19458253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NRG1/ERBB3 signaling inhibits melanocyte maturation and promotes undifferentiated, migratory, and proliferative characteristics; NRG1/ERBB3 signaling is necessary and sufficient to inhibit differentiation of late-stage melanocyte progenitors in culture. NRG1 treatment increases proliferation and invasion of melanocytes with decreased differentiation gene expression.\",\n      \"method\": \"ERBB3-deficient embryonic analysis, NRG1 treatment of melanocyte cultures, proliferation/invasion assays, gene expression analysis\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (ERBB3-deficient) plus gain-of-function (NRG1 treatment) with multiple functional and molecular readouts\",\n      \"pmids\": [\"19659570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LH induces NRG1 type III transcripts in granulosa cells via ERK1/2 and C/EBPβ-dependent mechanisms. NRG1 (intact 75 kDa and secreted 45 kDa forms) binds to ERBB3/ERBB2 complexes in granulosa cells and selectively stimulates AKT phosphorylation over ERK1/2. NRG1 potentiates AREG-induced ERK1/2 phosphorylation and progesterone production, and enhances oocyte developmental competence in cumulus-oocyte complexes.\",\n      \"method\": \"Western blotting, receptor phosphorylation assays, progesterone measurement, oocyte developmental competence assay\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional and biochemical readouts in granulosa cell and COC systems; single lab\",\n      \"pmids\": [\"21047912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Each of the six NRG1 isoform types has a distinct expression pattern in the brain at different developmental ages. Types I, II, and III are predominantly expressed in excitatory neurons. Neuronal activity specifically regulates NRG1 isoform expression: type I and IV NRG1 levels increase with neuronal activity. Type IV regulation requires a CRE cis-element in the 5' UTR that binds to CREB.\",\n      \"method\": \"Isoform-specific qPCR, in situ hybridization, CRE mutant reporter assay, ChIP-like analysis\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — activity-dependent regulation with CRE reporter assay identifying CREB binding; two orthogonal methods\",\n      \"pmids\": [\"21653853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NRG1 (ErbB2 ligand) inhibits GDNF-induced neuronal differentiation of mouse neural crest cells (enteric neuron precursors), while GDNF negatively regulates NRG1 signaling by down-regulating ErbB2 expression, establishing a functional interaction between RET/GDNF and NRG1/ERBB2 pathways in enteric nervous system development.\",\n      \"method\": \"Primary neural crest cell culture, neuronal differentiation assay, ErbB2 expression analysis after GDNF treatment\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional cell culture assay with receptor expression measurement; single lab with limited mechanistic depth\",\n      \"pmids\": [\"23400839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD74-NRG1 gene fusion leads to extracellular expression of the EGF-like domain of NRG1 III-β3, providing the ligand for ERBB2-ERBB3 receptor complexes. Ectopic expression of CD74-NRG1 in lung cancer cell lines expressing ERBB2 and ERBB3 activated ERBB3 and the PI3K-AKT pathway, and promoted anchorage-independent colony formation.\",\n      \"method\": \"Transcriptome sequencing, ectopic expression in cell lines, receptor phosphorylation assays, soft agar colony formation assay\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ectopic expression with phospho-receptor readout and functional colony assay; replicated across multiple tumor specimens and cell lines\",\n      \"pmids\": [\"24469108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NRG1 activates NR2B (GluN2B) phosphorylation through ErbB4, and TrkB interacts with ErbB4 (shown by co-immunoprecipitation and proximity ligation assay); this TrkB-ErbB4 interaction increases upon NRG1 treatment. TrkB inhibition (K252a, siRNA, TrkB-/- neurons) suppresses NRG1-induced NR2B activation. NRG1-induced BDNF release (via GABAAR-TrkB) mediates phospho-TrkB and phospho-NR2B increases; BDNF neutralization abolishes these effects.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, TrkB siRNA/knockout neurons, pharmacologic inhibition (K252a, AG1478), BDNF neutralization\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct protein interaction assays (co-IP + PLA) combined with multiple genetic and pharmacologic loss-of-function experiments, convergent mechanistic pathway\",\n      \"pmids\": [\"25052836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NRG1-ErbB4 signaling in the basolateral amygdala (BLA) modulates anxiety-like behaviors and GABA release but has no effect on glutamatergic transmission. ErbB4 is expressed almost exclusively in GABAergic neurons in the BLA; NRG1 administration into BLA alleviates anxiety and enhances GABAergic neurotransmission.\",\n      \"method\": \"Stereotactic NRG1 injection into BLA, electrophysiology (GABA release measurement), behavioral anxiety tests\",\n      \"journal\": \"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacologic activation with electrophysiology and behavioral readouts; mechanistic pathway placement in GABAergic interneurons\",\n      \"pmids\": [\"25308353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD74-NRG1 expression activates ErbB2/3 phosphorylation, PI3K/Akt/NF-κB signaling, and promotes cancer stem cell-like properties. NF-κB-dependent IGF2 expression and IGF1R phosphorylation are enhanced in CD74-NRG1-expressing cells, creating an IGF2 autocrine/paracrine circuit. Inhibition of ErbB2, PI3K, NF-κB, or IGF2 suppresses CD74-NRG1-induced tumor sphere formation.\",\n      \"method\": \"Ectopic expression, phospho-receptor/pathway assays, sphere formation assay, limiting dilution xenograft, pharmacologic inhibition\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including in vitro signaling assays, in vivo xenograft, and pharmacologic dissection of pathway components\",\n      \"pmids\": [\"26837769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DISC1 inhibits NRG1-induced ErbB4 activation and signaling in cortical interneurons; this inhibition is likely mediated by competitive inhibition of ErbB4 binding to PSD95. Cell-type-specific modulation of DISC1 in vitro and in vivo (including mutant DISC1 mouse model) demonstrated that DISC1 affects NRG1-ErbB4-mediated phenotypes in fast-spiking interneuron-pyramidal neuron circuits.\",\n      \"method\": \"Cell-type-specific gene modulation in vitro/in vivo, mutant DISC1 knock-in mouse, ErbB4/PSD95 binding competition assay, electrophysiology\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic in vivo model plus mechanistic binding competition assay plus electrophysiology; multiple orthogonal methods\",\n      \"pmids\": [\"26656849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Paracrine NRG1 from fibroblasts activates ERBB3 on uveal melanoma cells and provides resistance to MEK inhibitor trametinib; ERBB3 inhibition combined with MEK inhibition overcomes this resistance. Trametinib treatment enhances responsiveness to NRG1. AKT inhibition reverses the NRG1-mediated protective effect.\",\n      \"method\": \"Conditioned medium experiments, ERBB3/cMET inhibitor experiments, xenograft models, AKT inhibition rescue\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — paracrine mechanism established by conditioned medium + target inhibition experiments in vitro and in vivo; two orthogonal approaches\",\n      \"pmids\": [\"25952648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A RET-ER81-NRG1 signaling pathway in mechanosensory neurons is required for Pacinian corpuscle formation. ER81 is required downstream of RET for maintaining interaction with nonmyelinating Schwann cells; ER81 loss reduces NRG1 isoform expression (specifically the isoform not involved in myelination). Ablating Nrg1 in mechanosensory neurons eliminates Pacinian corpuscles, establishing a distinct NRG1 isoform-dependent pathway for axon-nonmyelinating Schwann cell communication.\",\n      \"method\": \"Genetic ablation (Er81 mutant, Nrg1 conditional knockout in neurons), Pacinian corpuscle histology, isoform-specific expression analysis\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple conditional genetic models with clear anatomical phenotype; epistasis established between RET, ER81, and NRG1 isoforms\",\n      \"pmids\": [\"27707970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VAMP2-NRG1 fusion gene is membrane-bound, displays the NRG1 EGF-like domain extracellularly, and promotes anchorage-independent colony formation in lung adenocarcinoma cells. Ectopic VAMP2-NRG1 expression stimulates phosphorylation of ERBB2, ERBB3, AKT, and ERK, confirming ERBB2/ERBB3 pathway activation as oncogenic mechanism.\",\n      \"method\": \"Whole-transcriptome sequencing, RT-PCR, immunoblotting, soft agar colony formation assay\",\n      \"journal\": \"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay (soft agar) plus phospho-signaling readout from ectopic expression; two orthogonal methods\",\n      \"pmids\": [\"26134228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Spironolactone acts as an antagonist of NRG1-ERBB4 signaling; it inhibits ERBB4 receptor phosphorylation and reverts cortical ERBB4 hyperphosphorylation in Nrg1 type III transgenic mice. Spironolactone increases spontaneous inhibitory postsynaptic currents in cortical slices, supporting ERBB4-mediated mode of action.\",\n      \"method\": \"Cell-based split TEV assay (compound screen), ERBB4 phosphorylation assay in transgenic mice, electrophysiology (cortical slice sIPSCs), behavioral tests\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstituted cell-based assay for drug screening plus in vivo transgenic validation plus electrophysiology; multiple orthogonal methods\",\n      \"pmids\": [\"28743784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NRG1 regulates Fra-1 expression and TNBC metastasis via the ERK1/2-Fbxw7-c-Myc pathway: NRG1 activates ERK1/2, which phosphorylates Fbxw7 and promotes its dissociation and nuclear import of c-Myc; c-Myc then drives Fra-1 transcription. NRG1 knockdown suppresses TNBC cell metastasis and Fra-1 downregulation.\",\n      \"method\": \"NRG1 knockdown, ERK1/2 activation assays, ubiquitination assays (Fbxw7-c-Myc), ChIP (c-Myc on Fra-1 promoter), metastasis assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissection via multiple molecular assays (ubiquitination, ChIP, kinase) in a single lab; mechanistic chain established\",\n      \"pmids\": [\"34992218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NRG1 fusions in pancreatic ductal adenocarcinoma (e.g., ATP1B1-NRG1, RBPMS-NRG1) drive ERBB receptor-mediated signaling. Pharmacologic ERBB inhibition (afatinib) resulted in clinical remission, functionally validating NRG1 fusions as ERBB pathway-activating oncogenic drivers in KRAS wild-type PDAC.\",\n      \"method\": \"Whole-genome and transcriptome sequencing, clinical ERBB inhibitor treatment with imaging response\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genomic identification plus clinical pharmacologic validation; functional mechanism inferred from therapeutic response\",\n      \"pmids\": [\"29802158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NRG1-Fc (NRG1 fused to IgG1 Fc) triggers potent AKT activation in the liver, lowers blood glucose, improves insulin sensitivity, and suppresses food intake in obese mice. NRG1-Fc acts as a FGF21 secretagogue; however, FGF21 is largely dispensable for its metabolic effects. NRG1-Fc directly targets hypothalamic POMC neurons to promote membrane depolarization and increase firing rate.\",\n      \"method\": \"NRG1-Fc fusion protein engineering, AKT phosphorylation assays, FGF21 neutralization, electrophysiology of POMC neurons, metabolic measurements in obese mice\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — engineered fusion protein with mechanistic dissection via FGF21 knockout (dispensable), direct POMC neuron electrophysiology, and hepatic signaling assays; multiple orthogonal methods\",\n      \"pmids\": [\"29515030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NOTCH1 signaling promotes ECM degradation during trabeculation while NRG1 promotes myocardial ECM synthesis, necessary for trabecular rearrangement and growth. NRG1 controls Vegfa expression, interconnecting the two systems that act antagonistically to establish trabecular architecture. These epistatic relationships were established using cardiac-specific mutant mouse models.\",\n      \"method\": \"Cardiac-specific mutant mouse models, confocal imaging, transcriptomic analysis, ECM quantification\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in multiple cardiac-specific mouse mutants with quantitative ECM and imaging readouts; published in high-impact journal with comprehensive mechanistic support\",\n      \"pmids\": [\"29743679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NRG1/HER3 axis mediates ERBB3 activation by pancreatic cancer-associated fibroblasts (CAFs) and tumor cells; the anti-NRG1 antibody 7E3 blocks NRG1-mediated HER3 activation, promotes ADCC in NRG1-positive cells, and inhibits pancreatic cancer cell migration and growth co-cultured with CAFs both in vitro and in vivo in orthotopic xenografts.\",\n      \"method\": \"Anti-NRG1 antibody blocking, ADCC assays, co-culture migration/growth assays, orthotopic xenograft model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody-mediated NRG1 blockade with receptor signaling and functional assays in vitro and in vivo; two orthogonal platforms\",\n      \"pmids\": [\"29935372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Nedd4l (E3 ubiquitin ligase) ubiquitinates NRG1 in the medial prefrontal cortex (mPFC) of stress-susceptible mice, reducing NRG1 protein levels without changing mRNA. Overexpression of Nedd4l in mPFC decreases NRG1 and causes stress vulnerability; downregulation of Nedd4l rescues NRG1 levels and attenuates depression-like behaviors.\",\n      \"method\": \"Ubiquitination assay, viral vector-mediated overexpression/knockdown, chronic social defeat stress model, RNA sequencing\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ubiquitination assay identifies Nedd4l as E3 ligase for NRG1, confirmed by bidirectional in vivo manipulation (OE and KD) with behavioral and molecular phenotypes\",\n      \"pmids\": [\"32703967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Dysfunctional ERBB3 or ERBB2 mutations (identified by trio-exome sequencing) cause reduced expression or altered phosphorylation of the mutant receptors (confirmed by RT-qPCR and immunoblot), leading to a developmental syndrome including HSCR, CIPO, peripheral neuropathy, and arthrogryposis. Single-cell RNA-seq and conditional ErbB3-deficient mouse models revealed a primary role for ERBB3 in enteric progenitors, establishing NRG1/ERBB3/ERBB2 signaling as essential for enteric nervous system development.\",\n      \"method\": \"Trio-exome sequencing, RT-qPCR on patient fibroblasts, immunoblot of mutant proteins, mouse scRNA-seq, conditional ErbB3 knockout mouse\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — human variant functional validation in patient cells plus conditional mouse model plus single-cell transcriptomics; multiple orthogonal methods converging on same pathway\",\n      \"pmids\": [\"33497358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CAF-derived NRG1 activates cancer cell ERBB2 and ERBB3 receptor tyrosine kinases to support KRAS*-independent growth in PDAC. Genetic extinction or pharmacological inhibition of KRAS* upregulates ERBB2 and ERBB3 expression. Genetic depletion or pharmacological inhibition of ERBB2/3 or NRG1 abolishes KRAS* bypass and synergizes with KRASG12D inhibitors.\",\n      \"method\": \"Genetic depletion/pharmacologic inhibition of ERBB2/3 and NRG1 in mouse and human PDAC models, KRAS* extinction models, combination drug studies\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and pharmacologic approaches in both human and murine PDAC models; epistasis between KRAS* and NRG1/ERBB signaling established\",\n      \"pmids\": [\"37775182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NRG1 regulates redox homeostasis in papillary thyroid cancer cells through the ERK pathway and NRF2, maintaining moderate ROS levels via ARE-containing antioxidant genes. NRG1 knockdown reduces cell viability and increases ROS, while NRG1 expression positively correlates with NRF2 in patient samples.\",\n      \"method\": \"NRG1 knockdown, ROS generation assay, intracellular GSH assay, Western blot for ERK/NRF2, CCK-8 assay\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional assays with loss-of-function in a single cell type; mechanistic pathway identified but single lab\",\n      \"pmids\": [\"29901070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Zenocutuzumab (bispecific anti-HER2×HER3 antibody) blocks NRG1 binding to HER3, inhibiting HER3 and AKT phosphorylation, inducing apoptosis markers, and inhibiting growth in NRG1 fusion-positive isogenic and patient-derived cell lines and xenograft models. This establishes that NRG1 fusions signal through HER3-HER2 heterodimerization as the primary oncogenic mechanism.\",\n      \"method\": \"Bispecific antibody blocking, phospho-HER3/AKT assays, apoptosis assays, PDX xenograft models, clinical response in patients\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mechanistic antibody blocking targeting specific ligand-receptor interaction validated in isogenic cells, PDX models, and clinical setting; multiple orthogonal methods\",\n      \"pmids\": [\"35135829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NRG1 fusions can stimulate downstream signaling through HER4 independently of other HER family members, and EGFR-HER3 signaling is also activated; pan-HER inhibition is more effective than selective HER2-HER3 targeting. Cetuximab (anti-EGFR) plus trastuzumab/pertuzumab (anti-HER2) yielded synergistic effects against NRG1 fusion-positive cells.\",\n      \"method\": \"Ba/F3 models engineered with individual HER family members plus NRG1 fusions, receptor phosphorylation assays, combination drug synergy assays, in vivo models\",\n      \"journal\": \"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — isogenic Ba/F3 system with individual HER members plus NRG1 fusions directly tests receptor contribution; multiple drug combination studies in vitro and in vivo\",\n      \"pmids\": [\"37678511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"M2-like macrophage-derived Nrg1 signals through ErbB2 and ErbB4 on cardiac fibroblasts via PI3K/Akt pathway to suppress hydrogen peroxide-induced senescence and apoptosis of fibroblasts in infarcted myocardium. Blockade of ErbB function accelerates both fibroblast senescence/apoptosis and exacerbates inflammation. This Nrg1/ErbB/PI3K/Akt anti-senescence mechanism regulates post-MI fibrotic tissue formation.\",\n      \"method\": \"M2 macrophage isolation and co-culture, ErbB pharmacologic blockade, senescence/apoptosis assays, in vivo MI model with ErbB blockade\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic assays with in vivo validation; identifies macrophage as cellular source and establishes PI3K/Akt pathway mechanistically\",\n      \"pmids\": [\"34997943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NRG1-ERBB3-mTORC2 signaling drives acinar specification in salivary glands: neuronal NRG1 activates epithelial ERBB3 to trigger lineage progression, secretion, and polarization of acinar progenitors via mTORC2. Genetic deletion of Erbb3 prevents acinar lineage progression and lumenized secretory acini formation; exogenous NRG1 treatment of isolated epithelia recapitulates acinar development.\",\n      \"method\": \"Single-cell RNA sequencing, Erbb3 conditional knockout, NRG1 treatment of isolated epithelia, mTORC2 pathway analysis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic loss-of-function (conditional KO) plus gain-of-function (NRG1 treatment of isolated tissue) plus single-cell sequencing to define pathway; multiple orthogonal approaches\",\n      \"pmids\": [\"36413949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Endocardial Nrg1 signals to myocardial ErbB2 to activate phospho-Erk, which regulates a transcriptional program for cardiomyocyte oriented cell division, trabeculation, and epithelial-to-mesenchymal transition-like migration. Loss of Nrg1 reduces cardiomyocyte Pard3 and Crumbs2 protein and alters cytoskeletal gene expression; ectopic Nrg1 overexpression causes S-phase arrest and prolonged trabeculation. Nrg1-dependent pErk activation controls Yap1 nuclear-cytoplasmic distribution.\",\n      \"method\": \"Cardiac-specific Nrg1 conditional knockout and overexpression mice, confocal imaging, transcriptomics, biochemical pErk/Yap1 assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — bidirectional genetic manipulation (KO + OE) with transcriptomics, imaging, and biochemical mechanistic validation of ErbB2-Erk-Yap1 pathway; multiple orthogonal methods\",\n      \"pmids\": [\"37846569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Zenocutuzumab, a HER2×HER3 bispecific antibody that blocks NRG1 binding to HER3, produced objective responses in 30% of patients with NRG1 fusion-positive solid tumors across 12 tumor types, confirming that NRG1 fusions drive oncogenesis through HER3-HER2 heterodimerization as the primary mechanism.\",\n      \"method\": \"Phase 2 registrational clinical trial with objective response assessment\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — prospective registrational trial with 204 patients across 12 tumor types; mechanistic target (NRG1-HER3-HER2) validated at clinical scale\",\n      \"pmids\": [\"39908431\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NRG1 (neuregulin-1) is a secreted/membrane-bound EGF-family ligand that binds primarily to ERBB3 (HER3) and ERBB4 (HER4), inducing heterodimerization with ERBB2 (HER2) — with ERBB2 serving as a co-receptor that decelerates ligand dissociation and amplifies signaling — thereby activating downstream PI3K/AKT, ERK/MAPK, and other cascades to regulate Schwann cell myelination, oligodendrocyte proliferation/differentiation, neuronal migration, cardiac trabeculation, and acinar specification, while oncogenic NRG1 gene fusions constitutively present the EGF-like domain on the cell surface, driving ERBB2-ERBB3/HER4-dependent tumorigenesis that is therapeutically targeted by the bispecific antibody zenocutuzumab.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NRG1 (neuregulin-1) is an EGF-family ligand that drives ErbB receptor tyrosine kinase signaling to control differentiation, proliferation, survival, and tissue morphogenesis across the nervous system, heart, and epithelia [#4, #28]. It binds with high affinity to ErbB3 and ErbB4 and induces receptor hetero-oligomerization into high-molecular-weight complexes, with ErbB2 (Neu/HER2) acting as a co-receptor that decelerates ligand dissociation and prolongs downstream activation of MAP kinase (ERK), SAPK/JNK, p38, and PI3K-coupled signaling [#0, #1, #3, #8]. NRG1 exists in multiple isoforms with distinct developmental and activity-dependent expression patterns, and type IV induction is CREB-dependent through a CRE element in its 5' UTR [#14]. Through ErbB receptors, NRG1 functions as a mitogen and survival/differentiation regulator for oligodendrocyte progenitors and Schwann cells (the latter via an autocrine loop), governs radial glial maintenance and neuronal migration partly via brain lipid-binding protein, and shapes Pacinian corpuscle formation and enteric nervous system development through specific isoforms [#4, #9, #6, #22, #31]. Peripheral myelination requires the PDZ protein Erbin, which stabilizes ErbB2 and sustains NRG1 signaling [#11]. In the heart, endocardial/myocardial NRG1-ErbB2-ERK signaling controls cardiomyocyte oriented division, trabeculation, ECM synthesis, and Yap1 localization, acting antagonistically with NOTCH1 [#28, #38]. NRG1 also signals to GABAergic ErbB4-expressing interneurons to modulate inhibitory transmission and anxiety, a pathway antagonized by DISC1 and pharmacologically by spironolactone [#18, #20, #24], and its abundance in the prefrontal cortex is controlled by Nedd4l-mediated ubiquitination in stress responses [#30]. NRG1 drives oncogenesis: chromosomal fusions (CD74-NRG1, VAMP2-NRG1, and others) present the EGF-like domain to activate ERBB2-ERBB3 (and HER4/EGFR) heterodimers and the PI3K-AKT axis, promoting transformation, while paracrine NRG1 from cancer-associated fibroblasts sustains ERBB3-AKT signaling and confers therapy resistance [#16, #23, #19, #21, #32]. NRG1 fusions signal primarily through HER3-HER2 heterodimerization, and the bispecific HER2\\u00d7HER3 antibody zenocutuzumab blocks NRG1-HER3 binding and produces clinical responses across NRG1 fusion-positive tumors [#34, #39].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that NRG1 (NDF) is a high-affinity ligand engaging Neu/HER2 plus an additional co-component and couples receptor activation to PI3-kinase, defining its receptor system.\",\n      \"evidence\": \"Radiolabeled NDF crosslinking, antibody blocking, and PI3K co-IP in mammary cells\",\n      \"pmids\": [\"8096177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the additional co-receptor not resolved\", \"Cell-type specificity of PI3K coupling unexplained\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Identified ErbB3 as a direct NRG1 receptor whose engagement induces hetero-oligomerization, answering which receptor transduces the ligand signal.\",\n      \"evidence\": \"125I-NDF crosslinking, anti-ErbB3 immunoprecipitation, and tyrosine phosphorylation assays\",\n      \"pmids\": [\"8045292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Composition of the >400 kDa complex not defined\", \"Relative contributions of ErbB2 vs ErbB4 not yet dissected\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined ErbB2's co-receptor mechanism, showing it decelerates ligand dissociation to prolong ERK/SAPK signaling, explaining how heterodimer composition tunes signal duration.\",\n      \"evidence\": \"Reciprocal co-IP, ER-trap intracellular antibody, ligand dissociation kinetics, and downstream kinase assays\",\n      \"pmids\": [\"8617201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of decelerated dissociation not shown\", \"Quantitative link between signal duration and cell fate not established\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Established NRG1 as a mitogen, survival, and differentiation-modulating factor for glial and neuronal lineages, defining its role in nervous system development.\",\n      \"evidence\": \"Oligodendrocyte/retinal cell proliferation, survival, and neurite assays with ErbB activation and antibody blocking\",\n      \"pmids\": [\"8780647\", \"8625831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform responsible not resolved\", \"In vivo relevance of differentiation inhibition incomplete\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Connected NRG1 to cortical development and Schwann cell biology, showing it drives radial glial maintenance/neuronal migration and an autocrine Schwann cell proliferative loop.\",\n      \"evidence\": \"In vitro migration assays, ErbB2-deficient mice, BLBP analysis, ELISA secretion detection, and antibody neutralization\",\n      \"pmids\": [\"9342043\", \"9417836\", \"9419971\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of BLBP induction downstream of NRG1 not detailed\", \"Isoform-specific autocrine signaling not yet dissected\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined NRG1 isoform diversity and activity-dependent transcriptional control, showing type IV induction is CREB-mediated, explaining how neuronal activity regulates ligand availability.\",\n      \"evidence\": \"Isoform-specific qPCR, in situ hybridization, and CRE reporter/CREB binding analysis\",\n      \"pmids\": [\"21653853\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of activity-induced isoforms in vivo not established\", \"Regulation of other isoforms incompletely defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified Erbin as an essential cofactor that stabilizes ErbB2 to enable NRG1-dependent peripheral myelination, revealing a structural requirement for signaling.\",\n      \"evidence\": \"Erbin-null and PDZ-deletion knockin mice, ErbB2 stability assays, Erbin-ErbB2 co-IP, and nerve conduction measurements\",\n      \"pmids\": [\"19458253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Erbin biochemically stabilizes ErbB2 not fully resolved\", \"Generalization beyond peripheral nerve untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed NRG1-ErbB4 signaling in GABAergic interneuron circuits and linked it to TrkB/BDNF and NMDA receptor regulation, defining its neuromodulatory role.\",\n      \"evidence\": \"Co-IP/PLA of TrkB-ErbB4, TrkB knockout/siRNA, pharmacology, BDNF neutralization, BLA electrophysiology and behavior\",\n      \"pmids\": [\"25052836\", \"25308353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ErbB4-TrkB binding interface not mapped\", \"Behavioral circuit specificity incompletely defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed DISC1 antagonizes NRG1-ErbB4 signaling via competition for PSD95 binding, providing a mechanistic node linking the pathway to interneuron circuit phenotypes.\",\n      \"evidence\": \"Cell-type-specific DISC1 modulation, mutant DISC1 knockin mice, ErbB4/PSD95 binding competition, electrophysiology\",\n      \"pmids\": [\"26656849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of DISC1-ErbB4-PSD95 competition unresolved\", \"Disease relevance not directly tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that NRG1 gene fusions (CD74-NRG1) present the EGF-like domain extracellularly to activate ERBB2-ERBB3 and PI3K-AKT, establishing NRG1 as an oncogenic driver.\",\n      \"evidence\": \"Transcriptome sequencing, ectopic fusion expression, phospho-receptor assays, and soft agar colony formation\",\n      \"pmids\": [\"24469108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Range of partner genes not fully cataloged\", \"Therapeutic targeting not yet defined at this stage\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended NRG1 fusion biology to additional partners and downstream circuits, including VAMP2-NRG1 membrane display and CD74-NRG1-driven NF-\\u03baB/IGF2 autocrine stemness.\",\n      \"evidence\": \"Ectopic fusion expression, phospho-signaling, sphere/colony formation, xenografts, and pharmacologic pathway dissection\",\n      \"pmids\": [\"26134228\", \"26837769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of IGF2 circuit across fusion types untested\", \"Relative oncogenic potency of different fusions not compared\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established paracrine NRG1 from cancer-associated fibroblasts as a driver of ERBB3-AKT signaling and KRAS-bypass/therapy resistance, defining a stromal source of pathway activation.\",\n      \"evidence\": \"Conditioned medium, genetic/pharmacologic ERBB2/3 and NRG1 inhibition in human and murine PDAC and uveal melanoma models\",\n      \"pmids\": [\"25952648\", \"37775182\", \"29935372\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Triggers of CAF NRG1 secretion not defined\", \"Clinical translatability of stromal targeting incompletely tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined NRG1-ErbB roles in organ morphogenesis and metabolism, including cardiac trabeculation/ECM synthesis, salivary acinar specification via mTORC2, and central metabolic control via POMC neurons.\",\n      \"evidence\": \"Cardiac-specific mutant mice, Erbb3 conditional KO with NRG1 epithelial treatment, scRNA-seq, and engineered NRG1-Fc with POMC electrophysiology\",\n      \"pmids\": [\"29743679\", \"37846569\", \"36413949\", \"29515030\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform/receptor selectivity across these tissues not unified\", \"Direct receptor identity for hypothalamic effect not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided human genetic and developmental evidence that NRG1/ERBB3/ERBB2 signaling is essential for enteric nervous system and peripheral neural development, linking the pathway to a Mendelian developmental syndrome.\",\n      \"evidence\": \"Trio-exome sequencing, patient fibroblast RT-qPCR/immunoblot, mouse scRNA-seq, and conditional ErbB3 knockout\",\n      \"pmids\": [\"33497358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pathogenic NRG1 variants (vs ERBB3/2) not directly demonstrated here\", \"Genotype-phenotype range incompletely defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified Nedd4l as the E3 ligase controlling NRG1 protein abundance post-translationally in the prefrontal cortex, linking ligand turnover to stress susceptibility.\",\n      \"evidence\": \"Ubiquitination assay and bidirectional viral Nedd4l manipulation in a chronic social defeat stress model\",\n      \"pmids\": [\"32703967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitination site on NRG1 not mapped\", \"Whether this regulates secreted vs membrane NRG1 unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Validated HER3-HER2 heterodimerization as the primary oncogenic mechanism of NRG1 fusions by demonstrating clinical efficacy of zenocutuzumab, which blocks NRG1-HER3 binding.\",\n      \"evidence\": \"Bispecific antibody mechanistic assays in isogenic/PDX models plus a Phase 2 registrational trial across 12 tumor types\",\n      \"pmids\": [\"35135829\", \"39908431\", \"37678511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Resistance mechanisms (HER4/EGFR contributions) require fuller dissection\", \"Predictors of the ~30% response rate not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How distinct NRG1 isoforms, membrane vs secreted forms, and receptor heterodimer combinations are matched to specific cellular outcomes across tissues remains incompletely defined.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model linking isoform to receptor heterodimer selectivity\", \"Quantitative rules relating signal duration to fate decisions absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 3, 16]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 3, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [16, 23]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [9, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 8, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 28, 37, 38]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [16, 19, 32, 34, 39]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [4, 18, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ERBB3\", \"ERBB2\", \"ERBB4\", \"ERBB1\", \"ERBIN\", \"NEDD4L\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}